Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer

Clinical Lung Cancer

Volumn 16, Issue 5, 2015, Pages 366-373

  Liang, Ying ^a   Wakelee, Heather A ^b   Neal, Joel W ^b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaplastic lymphoma kinase (ALK); Driver oncogene; Epidermal growth factor receptor (EGFR); KRAS; Non small cell lung cancer; NRAS; Pemetrexed; ROS1

Indexed keywords

ALANINE AMINOTRANSFERASE; BEVACIZUMAB; CARBOPLATIN; CREATININE; CRIZOTINIB; DOCETAXEL; ERLOTINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PLATINUM; ANTINEOPLASTIC AGENT; ONCOPROTEIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALK GENE; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EPISTAXIS; FATIGUE; FEMALE; GENE MUTATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEUKOPENIA; LUNG EMBOLISM; MAINTENANCE CHEMOTHERAPY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTIC SYNDROME; NEUROPATHY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; RHINITIS; ROS1 GENE; SIDE EFFECT; THROMBOCYTOPENIA; THROMBUS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PEMETREXED; PROTO-ONCOGENE PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84941414724     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.12.009     Document Type: Article

References (20)

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer, version 1.2015. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed: October 26, 2014.
2. G.V. Scagliotti, P. Parikh, J. von Pawel, and et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
3. N. Hanna, F.A. Shepherd, F.V. Fossella, and et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
4. T. Ciuleanu, T. Brodowicz, C. Zielinski, and et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 2009 1432 1440
5. L.G. Paz-Ares, F. de Marinis, M. Dediu, and et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer J Clin Oncol 31 2013 2895 2902
6. F. Barlesi, A. Scherpereel, A. Rittmeyer, and et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089) J Clin Oncol 31 2013 3004 3011
7. J.D. Patel, M.A. Socinski, E.B. Garon, and et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer J Clin Oncol 31 2013 4349 4357
8. D.R. Camidge, S.A. Kono, X. Lu, and et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed J Thorac Oncol 6 2011 774 780
9. J.O. Lee, T.M. Kim, S.H. Lee, and et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer J Thorac Oncol 6 2011 1474 1480
10. A.T. Shaw, A.M. Varghese, B.J. Solomon, and et al. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer Ann Oncol 24 2013 59 66
11. B.J. Solomon, T. Mok, D.W. Kim, and et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer N Engl J Med 371 2014 2167 2177
12. A.T. Shaw, D.W. Kim, K. Nakagawa, and et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2013 2385 2394
13. J.W. Riess, S.K. Padda, C.D. Bangs, and et al. A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non - small-cell lung cancer patients harboring ROS1 gene rearrangements Clin Lung Cancer 14 2013 592 595
14. P. Goldstraw, J. Crowley, K. Chansky, et al. for the International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumour J Thorac Oncol 2 2007 706 714
15. A.T. Shaw, B.Y. Yeap, M. Mino-Kenudson, and et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253
16. K. Bergethon, A.T. Shaw, S.H. Ou, and et al. ROS1 rearrangements define a unique molecular class of lung cancers J Clin Oncol 30 2012 863 870
17. D. Dias-Santagata, S. Akhavanfard, S.S. David, and et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine EMBO Mol Med 2 2010 146 158
18. E.M. Berge, X. Lu, D. Maxson, and et al. Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer Clin Lung Cancer 14 2013 636 643
19. K. Park, M. Ahn, C. Yu, and et al. ASPIRATION: First-line erlotinib (E) until and beyond RECIST progression (PD) in Asian patients with EGFR mutation-positive NSCLC Ann Oncol 25 2014 iv426 iv470
20. M.G. Kris, B.E. Johnson, L.D. Berry, and et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs JAMA 311 2014 1998 2006